Medeloop Pitch Deck: All 11 Slides + Teardown

The Academic-First Approach to Healthcare AI

Medeloop’s 11-slide deck, used to secure an $8M Seed round in 2023, is a focused narrative on efficiency. In a sector often bogged down by regulatory hurdles and slow adoption cycles, Medeloop chose to highlight the sheer length of the status quo. By quantifying the 'pain' in years rather than just dollars, they created a compelling case for AI intervention. The deck relies heavily on the founders' and advisors' ties to Stanford University, positioning the startup not as an outsider trying to disrupt medicine, but as an insider trying to fix it.

Slide 1: The Institutional Hook

The deck opens with a high-resolution image of the Stanford University campus. There is no text on this slide other than the caption provided in the metadata. This is a deliberate branding choice. For a healthcare startup, particularly one founded by researchers, leading with the 'Hoover Tower' at Stanford immediately establishes a geographic and intellectual pedigree. It signals that the technology is born out of one of the world's leading research ecosystems.

Slide 2: The Value Proposition

Slide 2 introduces the core promise: shrinking multi-year projects into weeks. It mentions the use of generative AI for grant writing and patient history collection. This is a timely inclusion for a 2023 raise, as it addresses the administrative 'drudge work' that consumes a researcher's time. By focusing on grants and medical histories, Medeloop identifies two high-friction areas that do not necessarily require clinical breakthroughs to solve, but rather better data orchestration.

Slide 3: Quantifying the Inefficiency

This is arguably the most important slide in the deck. It breaks the clinical research process into four distinct, time-consuming blocks:

Grant Application: .5 years with a <20% success rate. · Data Collection, Cleansing & Harmonization: 2-3 years. This is identified as the largest bottleneck where data is 'siloed and unstructured.' · Data Analysis: 1 year, described as a 'complex statistical task.' · Research Paper Writing: .5 years, described as 'tedious and time-consuming.'

By totaling these, Medeloop shows that a single research cycle takes 4 to 5 years. This quantification allows investors to visualize the ROI of a platform that can compress these timelines.

Slide 4: The AI-Driven Solution

Slide 4 introduces the Medeloop platform as the solution to the problems listed in the previous slide. It is described as an 'AI-driven platform that expedites the clinical research process.' While the slide is light on technical architecture, it serves as the bridge between the 'pain' of Slide 3 and the 'product' of Slide 5.

Slide 5: The Two-Sided Platform

Medeloop reveals its product interface here. The 'Researcher Portal' is shown on a laptop, featuring dashboards for biomarkers, experiment data ranges, and age insights. The 'Participant-Facing App' is shown on mobile devices, featuring food logs, calorie trackers, and stress reaction charts. This two-sided approach is critical; it suggests that Medeloop isn't just a data analysis tool, but a data collection tool that engages the patient directly, potentially solving the 'siloed data' problem mentioned on Slide 3.

Slide 6: The $83B Market Opportunity

The market slide focuses on the underserved nature of academia. It lists four key metrics:

$83B+: Amount spent by academic institutions on R&D annually. · $41B: Yearly NIH-supported research projects. · 25%: The portion of budget spent on IT services, data collection, and paper writing. · 56K: Sponsored NIH projects per year.

By highlighting that 25% of research budgets are already spent on the tasks Medeloop automates, the company demonstrates a clear 'Budgetary TAM' (Total Addressable Market). They aren't asking for new money; they are asking to capture a portion of the billions already being spent inefficiently.

Slide 7: The Go-To-Market Roadmap

The strategy is a classic 'Land and Expand.' The slide states that Medeloop is currently rolling out to universities (where they claim to have organic interest without marketing spend). The 'Next Year' goal is to sell to pharma and biotech companies. This transition is logical; universities provide the validation and data, while pharma provides the high-margin enterprise contracts.

Slide 8 & 9: The Pedigree Powerhouse

Slide 8 introduces the founding team (though names are omitted in the text summary, the context implies a Stanford-heavy roster). Slide 9 is a dedicated 'Advisors' slide featuring 10 individuals. The logos for Stanford Medicine, Yale, McGill, GSK, and Flatiron Health are prominently displayed. In a Seed round, investors are betting on the team's ability to navigate the industry. Having the VP of Product from Flatiron or a PhD from Stanford Business on the advisor list significantly de-risks the 'execution' aspect of the investment.

Slide 10 & 11: The Conclusion

The deck ends with a call to 'Join us in revolutionizing clinical research' and a standard 'Thank You' slide. Notably, there is no 'Ask' slide detailing the $8M raise or the specific use of funds. This suggests the deck was used as a visual aid for a pitch rather than a standalone document, or that the specific terms were handled in a separate data room.

What Medeloop Does Well

Quantified Pain Points: By breaking down the research process into years (Slide 3), they make the problem visceral. Every investor understands that '5 years to finish a project' is a massive opportunity for optimization.

Targeting the 'Unfashionable' Market: Many startups chase Pharma first because that is where the money is. Medeloop’s focus on the $83B academic market is smart. Academia is a massive, stable source of data and validation. If you win the researchers at Stanford and McGill, the Pharma companies will naturally follow to access that research.

Extreme Social Proof: Slide 9 is a 'who's who' of medical research. For a Seed stage company, this level of advisory support is rare and serves as a powerful signal that the product has real-world utility for the people who would actually use it.

What is Missing from the Deck

Competitive Landscape: The deck does not mention other clinical trial management systems (CTMS) or AI research tools like Elicit or Consensus. Investors would likely ask how Medeloop differentiates itself from legacy players like Veeva or emerging AI competitors.

Unit Economics: There is no mention of the pricing model. Is it a per-study fee? A per-researcher SaaS subscription? A percentage of the grant? Without this, the $83B market figure remains abstract.

The 'Ask': As noted, the deck omits the funding requirements. While common in 'leaked' decks, a standard pitch deck should typically include how much is being raised and what milestones that capital will hit (e.g., 'This $8M will allow us to onboard 20 universities and launch our Pharma pilot').

Founder's Playbook: What to Copy

The 'Timeline' Slide: If your product saves time, don't just say 'we are fast.' Map out the current timeline of your customer's life and show exactly where the days, months, or years are being wasted. Medeloop’s Slide 3 is a perfect template for this.

Budget-Based TAM: Instead of just showing a giant 'Healthcare is a $4T market' circle, Medeloop showed that 25% of a specific $83B budget is spent on the exact tasks they solve. This makes the market opportunity feel attainable and grounded in existing line items.

Leveraging Institutional Ties: If you are spinning out of a university or have a strong alumni network, use it. The Stanford imagery on Slide 1 and the advisor logos on Slide 9 do more to build trust than 50 slides of technical jargon ever could.